JP2025517355A5 - - Google Patents
Info
- Publication number
- JP2025517355A5 JP2025517355A5 JP2024568249A JP2024568249A JP2025517355A5 JP 2025517355 A5 JP2025517355 A5 JP 2025517355A5 JP 2024568249 A JP2024568249 A JP 2024568249A JP 2024568249 A JP2024568249 A JP 2024568249A JP 2025517355 A5 JP2025517355 A5 JP 2025517355A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- atrasentan
- pharmaceutically acceptable
- acceptable salt
- fsgs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343574P | 2022-05-19 | 2022-05-19 | |
| US63/343,574 | 2022-05-19 | ||
| PCT/US2023/022681 WO2023225163A1 (en) | 2022-05-19 | 2023-05-18 | Methods of treating focal segmental glomerulosclerosis with atrasentan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517355A JP2025517355A (ja) | 2025-06-05 |
| JP2025517355A5 true JP2025517355A5 (enExample) | 2026-05-11 |
Family
ID=88836135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568249A Pending JP2025517355A (ja) | 2022-05-19 | 2023-05-18 | アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250352511A1 (enExample) |
| EP (1) | EP4525857A4 (enExample) |
| JP (1) | JP2025517355A (enExample) |
| KR (1) | KR20250013180A (enExample) |
| CN (1) | CN119325377A (enExample) |
| AU (1) | AU2023271840A1 (enExample) |
| CA (1) | CA3252232A1 (enExample) |
| IL (1) | IL316349A (enExample) |
| MX (1) | MX2024013985A (enExample) |
| WO (1) | WO2023225163A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| US20170014386A1 (en) * | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| CA3010593C (en) * | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| IL294410B2 (en) * | 2016-11-23 | 2024-02-01 | Chemocentryx Inc | A method for the treatment of focal segmental tuberous sclerosis |
| HRP20260121T1 (hr) * | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
-
2023
- 2023-05-18 JP JP2024568249A patent/JP2025517355A/ja active Pending
- 2023-05-18 IL IL316349A patent/IL316349A/en unknown
- 2023-05-18 KR KR1020247041241A patent/KR20250013180A/ko active Pending
- 2023-05-18 AU AU2023271840A patent/AU2023271840A1/en active Pending
- 2023-05-18 CN CN202380039968.2A patent/CN119325377A/zh active Pending
- 2023-05-18 CA CA3252232A patent/CA3252232A1/en active Pending
- 2023-05-18 WO PCT/US2023/022681 patent/WO2023225163A1/en not_active Ceased
- 2023-05-18 EP EP23808292.9A patent/EP4525857A4/en active Pending
- 2023-05-18 US US18/867,358 patent/US20250352511A1/en active Pending
-
2024
- 2024-11-12 MX MX2024013985A patent/MX2024013985A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maes et al. | Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study | |
| EP3038654B1 (en) | New use | |
| US5686451A (en) | Combination of an ace inhibitor and a diuretic | |
| Cho et al. | Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity | |
| JP2013521303A5 (enExample) | ||
| HUP0400475A2 (hu) | Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| CN101420958A (zh) | 共投与腺苷a1受体拮抗剂和抗惊厥药 | |
| WO2026067059A1 (zh) | Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途 | |
| Hunsicker | Emerging Trends for Prevention and Treatment of Diabetic Nephropathy | |
| KR19980702099A (ko) | 심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제와 부작용-감소된 양의 알도스테론 길항제의 조합 치료요법 | |
| Lai et al. | The treatment of IgA nephropathy | |
| Cheung | Blockade of the renin-angiotensin system | |
| RU2024137883A (ru) | Способы лечения фокально-сегментарного гломерулосклероза с помощью атразентана | |
| Esmail et al. | Losartan as an alternative to ACE inhibitors in patients with renal dysfunction | |
| Woo et al. | Clinical trials of the past decade in the management of chronic kidney disease | |
| WO2008121882A1 (en) | Improved methods of administration of adenosine a1 receptor antagonists | |
| TWI281858B (en) | Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors | |
| US20250352511A1 (en) | Methods of treating focal segmental glomerulosclerosis with atrasentan | |
| KR19980702100A (ko) | 심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제, 부작용-감소된 양의 알도스테론 길항제 및 이뇨제의 조합 치료요법 | |
| ES3062063T3 (en) | A pharmaceutically acceptable salt of atrasentan for use in a method of treating iga nephropathy | |
| WO2005046677A2 (en) | At1-receptor antagonists for treating nephrotic syndrome | |
| AU2004229026A1 (en) | Mycophenolate mofetil in diabetic nephropathy | |
| CN115737638A (zh) | 一种阿利沙坦酯吲达帕胺复方药物组合物的新应用 | |
| EP4419097A1 (en) | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy | |
| Iniguez et al. | P-217: Effectiveness and tolerability of enalapril plus nitrendipine on a fixed dose in hypertensive patients over 65 years |